Frequently Asked Questions

1. Any clinical information of the cohort?

This study included 683 recipients who received haploHCT from January 2018 to June 2021 and their respective donors. All patients were diagnosed as hematopoietic malignancy and achieved complete remission before transplantation. All patients and healthy donors included in this study have signed informed consent form. The study protocol has been approved by the Ethics Committee of Peking University People’s Hospital.

2. What's the transplant protocol of this study?

We used T-cell-depleted approach for HLA-haploidentical HCT (haploHCT), namely, the antithymocyte globulin (ATG)/granulocyte colony-stimulating factor (G-CSF)-based "Beijing protocol".

3. How do I find the analysis workflow and customized scripts of this study?

We provided the analysis pipeline at github. Please find the detailed information at https://github.com/gao-lab/aGVHD.

4. What version of the human genome sequence are the data mapped to at aGVHD database?

All data in the database is currently mapped to hg38.

5. What does "NA" results mean in OR or P-value?

It means all the samples share same genotypes which is not sufficient for logistic regression.

6. Why there is "*" after the gene name?

It means the variant located in the intronic region.

7. How can I get more data of this study?

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Xiao-Jun Huang ([email protected]).